Guardant Health, Inc. (NASDAQ:GH) Stock Holdings Raised by Hsbc Holdings PLC

Hsbc Holdings PLC lifted its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 25.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 19,011 shares of the company’s stock after purchasing an additional 3,863 shares during the period. Hsbc Holdings PLC’s holdings in Guardant Health were worth $582,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Guyasuta Investment Advisors Inc. bought a new position in Guardant Health during the 4th quarter worth approximately $206,000. Entropy Technologies LP acquired a new stake in shares of Guardant Health during the 4th quarter valued at approximately $377,000. Raymond James Financial Inc. acquired a new position in Guardant Health in the fourth quarter worth $2,211,000. Swiss National Bank increased its stake in Guardant Health by 1.0% during the fourth quarter. Swiss National Bank now owns 241,900 shares of the company’s stock valued at $7,390,000 after purchasing an additional 2,500 shares during the last quarter. Finally, Rhumbline Advisers raised its holdings in shares of Guardant Health by 2.2% during the fourth quarter. Rhumbline Advisers now owns 167,230 shares of the company’s stock worth $5,109,000 after purchasing an additional 3,529 shares during the period. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently weighed in on GH. Mizuho initiated coverage on shares of Guardant Health in a research report on Thursday, April 10th. They set an “outperform” rating and a $55.00 price objective for the company. Raymond James restated an “outperform” rating and issued a $59.00 price target (up previously from $39.00) on shares of Guardant Health in a research note on Friday, February 21st. JPMorgan Chase & Co. boosted their price objective on Guardant Health from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. UBS Group raised their target price on Guardant Health from $65.00 to $70.00 and gave the company a “buy” rating in a research report on Thursday, May 1st. Finally, TD Securities boosted their price target on Guardant Health from $56.00 to $60.00 and gave the stock a “buy” rating in a research report on Thursday, May 1st. Twenty-one investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $52.32.

Insider Transactions at Guardant Health

In related news, CEO Amirali Talasaz sold 106,784 shares of the company’s stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $49.01, for a total transaction of $5,233,483.84. Following the transaction, the chief executive officer now directly owns 2,202,672 shares of the company’s stock, valued at approximately $107,952,954.72. The trade was a 4.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 107,132 shares of company stock valued at $5,249,355 over the last ninety days. Corporate insiders own 5.50% of the company’s stock.

Guardant Health Stock Down 4.7 %

Shares of NASDAQ GH opened at $41.98 on Wednesday. The stock’s fifty day simple moving average is $43.76 and its 200 day simple moving average is $38.54. The stock has a market capitalization of $5.20 billion, a price-to-earnings ratio of -11.79 and a beta of 1.49. Guardant Health, Inc. has a 52-week low of $18.01 and a 52-week high of $52.92.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.08. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The firm had revenue of $203.47 million for the quarter, compared to analysts’ expectations of $189.91 million. During the same quarter last year, the business posted ($0.46) EPS. Guardant Health’s revenue was up 20.8% on a year-over-year basis. As a group, analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.